ABSTRACT Type 2 innate lymphoid cells were found to be members of the innate immune cell family, which is involved in innate and adaptive immunity to resist the invasion of foreign antigens

and induce allergic reactions caused by allergens. The advancement of ILC2 research has pointed out that ILC2s have a high degree of diversity, challenging the notion of their homogeneity as

a cellular population. An increasing number of studies indicate that ILC2 is a cell population with tissue specificity which can be induced by the tissue microenvironment. In addition,

crosstalk between tissues can change ILC2 functions of migration and activation. Here, we emphasize that ILC2 undergoes adaptive changes under the regulation of the tissue microenvironment

focused on the function of ILC2 in inter-tissue crosstalk. Lastly, we discussed the transdifferentiations of ILC2 caused by the abnormal change in tissue environment. SIMILAR CONTENT BEING

VIEWED BY OTHERS THE MODULATION OF PULMONARY GROUP 2 INNATE LYMPHOID CELL FUNCTION IN ASTHMA: FROM INFLAMMATORY MEDIATORS TO ENVIRONMENTAL AND METABOLIC FACTORS Article Open access 11

September 2023 NEUROPILIN-1 MEDIATES LUNG TISSUE-SPECIFIC CONTROL OF ILC2 FUNCTION IN TYPE 2 IMMUNITY Article 24 January 2022 MATURATION AND SPECIALIZATION OF GROUP 2 INNATE LYMPHOID CELLS

THROUGH THE LUNG-GUT AXIS Article Open access 09 December 2022 FACTS * 1. ILC2s play an essential role in both innate and adaptive immunity. * 2. ILC2 derived from different tissues shows

significant differences in phenotype due to exposure to different tissue microenvironments. * 3. The tissue crosstalk can be caused by ILC2 migration. * 4. The distal or proximal tissue

microenvironment can induce the transformation, activation, and inhibition of tissue-resident ILC2. OPEN QUESTIONS * 1. Can drugs treat tissue injury caused by ILC2s by targeting the

tissue-specific phenotype of ILC2? * 2. Whether ILC2 in different tissues is functionally significantly different from each other? INTRODUCTION ILC2s, as members of the ILC family, play an

important role in innate and adaptive immunity. Previous studies showed that ILC2s are deeply involved in maintaining tissue homeostasis, activating immunity, and regulating metabolism

[1,2,3]. They rapidly respond to replay early innate immune responses on pathogen infection and tissue damage by directly delivering signals to hematopoietic and non-hematopoietic cells [4,

5]. Although lacking adaptive antigen receptors, ILC2s participate in the regulation of adaptive immune response by secreting immunomodulatory cytokines to direct the immune reaction of

helper cells and expressing major histocompatibility complex (MHC) class II to deliver antigen information to adaptive immune cells [6, 7]. Previously, ILC2s were considered homogeneous

cells marked with transcription factors: GATA3 and RORα [8]. However, research on both human and mouse ILC2s has revealed that ILC2s are a heterogeneous population of cells with different

gene expressions. The transcriptional profile, phenotype, and function of ILC2s can change with the microenvironment in which they reside. These phenomena prompt that the physiological

effects of ILC2s are also different [9, 10]. Due to differences in cell composition, cytokine levels, chemokine levels and inflammatory factor levels in the living microenvironment, resident

ILC2 possesses heterogeneity between organizations. This character has been called tissue specificity [11]. At the same time, ILC2s can change their transcriptional profile, phenotype and

even function to adapt to the tissue environment for exerting effective immunity. Tissue-resident ILC2s exhibit differences in immune responses, including the degree of response to

cytokines, conditions required for the secretion of type 2 cytokines, and the function of tissue repair, and so on [12]. In addition to being influenced by the tissue microenvironment, ILC2

can also accept signaling factors that undergo regulation from distal or proximal tissues [13]. And ILC2s also interact with distal tissues to participate in the tissue immune responses [13,

14]. ILC2 is a highly plastic cell population. Tissue ILC2s not only have the potential to transform into other ILC2 subtypes but also transdifferentiate from one subset into another [15].

Studies have revealed that the tissue environment contributed to ILC2 transdifferentiation. However, the abnormality of ILC2 in transdifferentiation can amplify tissue inflammation and

induce unprotective type 1 or 3 immune responses [16]. In this review, we elucidate that the tissue microenvironment mainly induces the tissue-specific formation of ILC2 by producing

cytokines and influencing the differentiation of congenital lymphoid progenitor cells. Then, we listed recent research about the tissue specificity of ILC2 derived from various tissues,

which revealed that ILC2s in different tissues had differences in gene profile, transcriptional profile, and phenotype. Considering the regulatory effect of distal tissues on other tissue

ILC2s, we also summarized the latest experimental results, which have found the crosstalk between different tissues can be achieved by influencing the development of ILC2. Then we discussed

the transdifferentiation of ILC2 induced by tissue environment and the effect of abnormal ILC2 transdifferentiation. CHARACTERISTIC OF GROUP 2 ILCS ILCs derive from common lymphoid

progenitor (CLP) and can be simply divided into three groups: group 1 ILCs, group 2 ILCs, and group 3 ILCs, based on the differential requirement of transcription factors, the production of

signature cytokines, the special phenotypic markers and distinctive effector function [4, 17]. ILC2 is a single subset in group 2 ILCs, and its development depends on the activation of

transcription factors: GATA-3, Bcl11b, RORα, TCF- 1, and Gfi1 [18, 19]. ILC2s can be activated by myeloid-cell- or epithelial-cell-derived cytokines (TSLP, E-cadherin, TL1A), alarmins

(IL-25, IL-33) and inflammatory mediator (IL-2, IL-4, IL-7, IL-9). Then ILC2s generate a host of cytokines, including IL-5, IL-6, IL-9, and IL-13, to protect against pathogens and induce

eosinophilic inflammation by associating type 2 immune response [6]. (Fig. 1) According to previous studies, ILC2s also exert essential effects on repairing tissue damage by amphiregulin

production, improving proliferation and differentiation of epithelial cells and further restoring barrier integrity and airway remodeling [20]. Although ILC2s have been proven to have a

positive effect on sustaining tissue homeostasis, ILC2 plays an important role in promoting the development of allergic disease and inflammation in the lungs, kidneys, et al., which

ultimately result in tissue damage and functional dysregulation. In particular, the lung-resident ILC2s have been revealed to be deeply implicated in promoting pathologic inflammation in

allergic asthma through activating Th2 cells and releasing IL-5 and IL-13 to recruit eosinophils and increase mucus production [21]. Nowadays, there is various research on inhibiting

activation and immune responses of ILC2s for ameliorating allergic asthma [22,23,24]. However, ILC2s may not refer to a single-cell population. Huang et al. divided ILC2s into ST2-17RB+

inflammation ILC2s (iILC2s) and ST2+17RB- nature ILC2s (nILC2s) and described the difference between the two groups. nILC2s maintain a stable state in tissue and quickly respond to IL-33. On

the contrary, iILC2s are undetectable in a steady state and mainly respond to IL-25 [25]. What’s more, Cai et al. have proved that ST2+ ILC2s exist ST2+IL17+ ILC2s subset, which produced

adequate IL-17 to promote lung inflammation, and IL17-/- ILC2s have little effect on this disorder [26]. As mentioned above, ILC2s not only induce allergic diseases but also maintain tissue

homeostasis and repair tissue. Excessive inhibition of ILC2 may result in tissue immune disorders, thereby affecting the dysfunction of other tissues and even the whole body. Therefore, the

question of identifying the main pathogenic subsets in ILC2 and targeting those cells for treating autoimmune diseases should also be of concern. ILC2S INVOLVE BOTH INNATE IMMUNITY AND

ADAPTIVE IMMUNITY ILC2, a type of cell involved in the initial immune response, is both closely related to innate and adaptive immunity. ILC2 mainly plays a role in recruiting inflammatory

cells, secreting type 2 inflammatory factors, and repairing tissues in innate immunity, while in adaptive immunity, ILC2 mainly promotes T cell activation and proliferation. THE EFFECTS OF

ILC2S ON INNATE IMMUNITY As we know, ILC2s are distributed within the barrier and play an important role in innate immunity, being one of the initial responders of pathogen invasion (Fig.

2). With the stimulation of alarm factor of IL-33, IL-25 and TSLP induced by allergens or helminth, ILC2 can secrete type 2 cytokines, IL-4, IL-13 and IL-5, to participate in innate immune

responses [27]. IL-13 can induce epithelial eotaxins and endothelial adhesins necessary for eosinophil trafficking and promote goblet cell proliferation and mucus secretion to facilitate

worm elimination [28, 29]. Due to the function of IL-5 in promoting activation, recruitment, and survival of eosinophils, IL-5 secreted by ILC2 supports the involvement of eosinophils in the

early phase of allergic inflammation [30, 31]. IL-9 has been proposed to induce mucous production, goblet cell hyperplasia and airway remodeling and plays an important role in the

development of allergic lung disease via promoting the production of IL-5 and IL-13 in ILCs. ILC2 not only promotes the activation and aggregation of immune cells but also has the function

of tissue repair and maintaining tissue homeostasis. In addition, ILC2 has been confirmed to have the potential to release IL-9, further fostering the resolution of inflammation and

restoring immune homeostasis in chronic inflammatory diseases [32, 33]. Under the stimulation of epithelial alarm factor IL-33, ILC2 can produce amphiregulin (AREG) with tissue repair and

immune tolerance functions [34]. According to a host of studies, the epidermal growth factor (EGF)-like molecule AREG plays a critical role in type 2-mediated resistance and tolerance, which

could reduce autoimmune attacks caused by worm or non-worm infections, alleviate local tissue inflammation, promote tissue repair, and maintain the integrity of tissue [35]. THE EFFECTS OF

ILC2S ON ADAPTIVE IMMUNITY ILC2 not only plays an essential role in innate immunity but also has the function of promoting adaptive immunity, mainly reflected in promoting T cell

proliferation and activation to enhance adaptive immune effects. (Fig. 3) ILC2s can promote T cell proliferation and type 2 cytokine production (including IL-5 and IL-13) of CD4+ T cells via

cellar contact and secretion of IL-4 [36]. Moreover, Oliphant et al. found in depleted-ILC2 mice that the ability of CD4+T cells to produce IL-13 and IL-5 and expulsion of _N. brasiliensis_

was impaired, and revealed that ILC2 promotes CD4+T cell proliferation and activation through antigen induction caused by expression of MHC II and present antigen to the T cell. The

promoting effect of ILC2 on T cell immune response has also been confirmed in vitro coculture of human-derived ILC2 and CD4+ T cells [37]. After the initiation of the adaptive immune

response, native CD4+ T cells will differentiate into helper T(Th) cells, including Th1, Th2, Th9, Th17, etc, to resist antigens. And ILC2 is closely related to the production and activation

of Th2 cells [38]. Th2 cells are the core of type 2 immunity, and their activation is initiated by the recognition of antigens on antigen-presenting cells [39]. ILC2s serve as an innate

counterpart of adaptive effector Th2 cells, which can be directly activated by alarmins to produce type 2 cytokines. Although Th2 cells can be activated independently of ILC2, the activation

of ILC2s enhances Th2 cell production and immune response [40]. Recent studies have shown that ILC2s promote Th2 cells to participate in type 2 immunity by promoting Th2 cell

differentiation. Pelly et al. found that Th2 cell differentiation in mice infected with H. polygyrus depended on ILC2-derived IL-4 [41]. In addition, ILC2 can promote the migration of

activated DC to the mediastinal lymph nodes to induce native CD4+ T cells to differentiate into Th2 cells [42]. There are also studies indicating that ILC2 can amplify the activation of Th9

cells, but the specific mechanism has not yet been revealed [43]. In addition to participating in the immune response of CD4+ T cells, ILC2 can also act on Treg cells and γδT cells to

exacerbate allergic inflammation. IL-4 production by ILC2 promotes the food allergic response by reducing allergen-specific Treg cells and activating mast cells [44, 45]. Moreover, ILC2s

play a key role in the activation of tissue-specific immune responses in the lung and adipose. OX40L expression by ILC2s is required for IL-33 to drive tissue-restricted Th2 and Treg cell

expansion [46]. ILC2s activated by NUM contribute to IL-17-producing γδT cells proliferation and secretion of IL-17A [47]. THE TISSUE-SPECIFIC FEATURES OF ILC2 At first, people thought that

ILC2 was a homogeneous cell group that expressed specific transcription factors and cytokines. However, a large number of experiments have shown that ILCs, especially ILC2s, exhibit

heterogeneity in phenotype, and function [48]. In recent years, studies have found a unique subset of ILC2 cells that can secrete IL-10, an anti-inflammation factor, in both mice and humans,

which possess the effect of inhibiting immune cell proliferation [49, 50]. Transcription data indicated that the gene expression of IL-10+ ILC2 is different from that of IL-10- ILC2. Its

expression of _Retnla_ is upregulated, which is Th2 response negative regulatory factor. Meanwhile, the expression of _Tnf_, _Lta_, _Il2_, and _Ccl1_, pro-inflammatory factors, is

downregulated, indicating that it has a different anti-inflammatory effect from other ILC2 [49]. Interestingly, intestinal ILC-derived IL-10 is mainly derived from IL-10+ILC2s rather than

ILCregs, which have been shown to be similar to Treg cells and participate in intestinal IL-10 secretion [51]. Other studies also revealed that ILC2 subsets that express c-kit markers have

distinct transcription and function. c-kitlo ILC2 subset displayed greater potential to produce type 2 cytokines, while c-kithi ILC2 exhibited an ILC3-like signature, which coexpressed the

marker and cham chemokine receptor CCR6 of ILC3 and was able to produce a significant IL-17A under ILC3-promoting condition [15, 52]. Moreover, Huang et al. discovered a new ILC2 subgroup,

inflammation ILC2, in the lungs of mice treated with IL-33. Their research suggests that iILC2 is different from the ILC2 that naturally resides in the lung, which has the ability to migrate

and is involved in the defense of early worm invasion in the lung [53, 54]. The heterogeneity of ILC2 is not only reflected between ILC2 subpopulations but also between different tissues.

Numerous studies have shown that ILC2 derived from different tissues exhibit significant differences in gene profile, transcriptional profile, and phenotype due to the presence of different

microenvironments and stimulation of biological signals [55]. These differences are even greater than those between ILC2, ILC1, and ILC3 [11]. The following will provide a detailed

introduction to the tissue specificity of ILC2 in different tissues. THE TISSUE-SPECIFIC FEATURES OF LUNG ILC2 The lung-resident ILC2s exhibit tissue-specific features in phenotypic

receptors and expression of regulators. (Fig. 1a) As mentioned above, ILC2 can be directly activated by alarm factors, IL-25 and IL-33, to participate in the initial type 2 immune response.

However, lung ILC2s show differences in the degree of response to cytokines due to the expression of cytokine receptors. Steady-state lung ILC2s highly express ST2 (IL-33 receptor) and

produce type 2 cytokines following the stimulation of IL-33 [56], but these ILC2s hardly responded to IL-25 alone because they expressed IL17RB (IL-25 receptor) at a low level [57]. However,

cysteinyl leukotrienes secreted by tuft cells can synergize with IL-25 to activate ILC2s and further highly polarize type 2 immune responses [58]. Compared to the transcriptional profile

with tonsil and blood ILC2, lung ILC2 derived from humans has a high presence (35%) of CRTH2- ILC2, which could not be found in tonsil or blood ILC2. Moreover, lung ILC2 are more activated

and express higher receptors for the ILC2-activating alarmins IL-33 and IL-25 than tonsil and blood ILC2. Interestingly, the expression of IL-1RL1 and IL-17RB was increased in blood ILC2,

and the expression of CRTH2 was downregulated after exposure to ILC2-activating alarms, including IL-2, IL-25, IL-33, and TSLP, which demonstrated that the phenotypic changes related to

tissue microenvironment [11]. Zao et al. reveal that CCR2 serves as a tissue-specific marker in lung ILC2 and may play an important role in ILC2 re-localization from Bone Marrow (BM) to the

lung [54]. Neuropilin-1 is also a tissue-specific marker of lung ILC2, which can enhance ILC2 pro-inflammation function and type 2 immunity by upregulating ST2 expression. Another research

points out that Nrp1 in lung ILC2 is closely related to pulmonary fibrosis [55, 59]. Notably, because the receptors for ILC2 in tissues are partly tissue-specific, these receptors may become

targets for treating excessive type 2 immunity in the tissues. Wang et al. found HTR2A was highly expressed in ILC2s from mouse lungs and human PBMC. Then, they use antagonists targeting

HTR2A receptors in lung ILC2s to suppress type 2 lung immune response induced by ILC2 activation [60]. In addition to the tissue-specific features, lung ILC2 is heterogeneous and the single

population of lung ILC2 may exert different functions in immunity and tissue repair. In a 2019 experiment, RORα- YFP mice, whose cells express _Rorα_ during their development and can be

irreversibly labeled by Yellow Fluorescent Protein (YFP), were used to analyze the heterogeneity of lung ILC2s. RORα-YFP ILC2 from adult mouse lung could be divided into two subsets

according to the difference in expression level of ILC2-associated genes (_Il1rl1, Tnfrsf18, Areg, Arg1, Cd7, Runx3, Cd2, Tcf7, Il18r1_). Moreover, distinct effector ILC2 subsets (KLRG+ICOS-

and KLRG-ICOS+ ILC2 subsets) in neonatal mouse lungs were discovered, which mainly produced pro-inflammation cytokines (IL-5 and IL-13) or amphiregulin promoting tissue repair [61]. THE

TISSUE-SPECIFIC FEATURE OF GUT ILC2 Aryl hydrocarbon receptor (Ahr) is a ligand-dependent environment sensor that was thought to be part of the tissue adaptation mechanism in cells promoting

the host to adapt to external environmental changes. (Fig. 1b) Compared to ILC2s in the lung, fat, mesenteric lymph nodes, skin, or blood, gut ILC2s in mice highly express Ahr, and the

expression of Ahr in gut ILC2 was supported by the gut environment. Interestingly, Ahr could suppress ILC2 function, inhibiting the expression of IL-33 receptor and effector molecules IL-5,

IL-13 and amphiregulin. This finding indicated that the gut ILC2s process tissue-specific features and the function of gut ILC2s may differ from other ILC2s distributed in other tissues or

blood [62]. Jinxin Qiu et al. not only confirmed Ahr to be an intestine ILC2s feature but also found _Ikzf3_ encoding the transcription factor Aiolos as the tissue-specific feature by

investigating the differential expression of the gene in mice and humans. (Fig. 1b) Aiolos can regulate the function of immune cells, including ILC2s, which can sustain IL-5 expression in

ILC2s and promote eosinophil recruitment by inhibiting PD-1. Notably, this study also found that Ahr plays an important role in the long-term maintenance and IL-5 production of ST2+ ILC2s

through sustaining Aiolos expression and inhibiting PD-1. The regulation of Aiolos expression by Ahr in ILC2s implies that the mechanism of maintaining functions of ILC2s in the intestine is

different from other tissue ILC2s [12]. THE TISSUE-SPECIFIC FEATURE OF SKIN ILC2 The skin is the outermost barrier between the environment and internal organs that contain cells of the

immune system deployed as sentinels that serve as a first line of defense against microbial attacks. As one of the components of mucosal immunity, the skin also contains ILC2 cells. A

previous study proved that a population of CD45+CD11b-CD90hiCD3-CD2- ILC2s exerted in wild-type mice dermis, which uniquely expressed CD103 and lacked some of the characteristic markers of

ILC2s, such as CD25, Sca-1, CD117 and ST2, being different with other mucosal ILC2s [63].(Fig. 1c) And the expression proportion of skin ILC2 cytokine receptor also has tissue specificity.

Skin ILC2 all expresses IL-18Rα, which differs from ILC2 groups from the lung and bone marrow, where only 5% -10% of ILC2 express IL-18 receptors. IL-18 was an essential cytokine to

proliferate skin IL-18Rα+ST2- ILC2 and produce IL-5 and IL-13 in a model of atopic dermatitis. However, IL-18 cannot effectively activate lung _Il5__+_ ILC2s to produce IL-13 [61].

Single-cell sequencing was used to detect ILC2 sorted from the skin, revealing that the transcription profile of skin ILC2 was significantly different from ILC2 in the bone marrow and other

peripheral tissues. Although skin ILC2s broadly express _Gata3_, _Il7r_, and _Crlf2_, the expression of _Icos_, _Ccr6_, and _Itgae_ is highly enriched in skin ILC2s and expression of

_Il1rl1_ in skin ILC2s is less than lung and adipose ILC2s [64]. Moreover, the phenotype and function of skin ILC2s can be induced to change when the microenvironment is changed by diseases.

In psoriasis induced by IL-23 or imiquimod, the resting ILC2 population in the skin can specifically transform into an ILC3-like subset and participate in the immune response of psoriasis

to promote skin inflammation [15]. THE RELATION BETWEEN TISSUE MICROENVIRONMENT AND TISSUE-SPECIFIC IN ILC2S ILC2s possess the ability to change their function to adapt to various tissue

microenvironments, which contributes to tissue ILC2s having tissue-specific characteristics. Many researchers have reported that tissue microenvironments can induce ILC2 to acquire

tissue-specific features through cytokines and the differentiation of ILC progenitor cells (ILCP). TISSUE MICROENVIRONMENT PROMOTES THE DIFFERENTIATION OF ILCP INTO TISSUE-SPECIFICAL ILC2

ILC progenitors can seed tissues during the prenatal period [65]. And ILC2 can be found in various tissues during late gestation. However, a majority of peripheral ILC2s were distributed in

tissues during the post-natal window and quickly expanded and differentiated to consist of tissue-resident ILC2 pools. This period was accompanied by the acquisition of tissue-specific

transcriptomes, which suggests that the tissue specificity of ILC2 can be shaped by the differentiation of early immature ILC2 induced by the tissue microenvironment in which ILC2s were

located [66]. In addition to deriving from the naive ILC2s that were generated in the period from birth through weaning, tissue ILC2s can be produced by the differentiation of local ILCPs

and mature in the tissue. Naive Il18r+ST2− ILCs, the local ILCP with differentiation ability, were found in mice and humans’ lungs, contributing to the expansion of lung ILC2s. What’s more,

when lungs were infected by _N. brasiliensis_, BM Il18r+ ST2−ILCs were recruited into the lungs and can generate the entire spectrum of lung ILC2s based on their single-cell transcriptomes.

These results imply that ILCP, located in various tissues, retains the potential to differentiate into tissue ILC2s, and this differentiation process may be guided by the tissue

microenvironment [67]. In addition, studies have found a type of ILC precursor cell, CD62L+ ILCP, which mainly differentiates into ILC2. However, in psoriasis patients, CD62+ ILCP is

reduced, while the number of CD62- is upregulated, and these cells tend to differentiate into ILC3s, which enrich in psoriasis. This research indicated that the proliferation of precursor

cells of ILC2 is influenced by the disease environment [68]. CYTOKINES IN TISSUE MICROENVIRONMENT SUPPORT PHENOTYPIC CHANGES IN MATURE ILC2 With the development of research on tissue ILC2,

it has been gradually discovered that the secreted products of tissue can promote the expression of tissue-specific phenotypes in ILC2. As we know, resting IL-5+ ILC2s required the

stimulation of epidermal cytokines, IL-33, IL-25, and TSLP, to produce type 2 cytokines [69]. However, in the mice triple-deficient in TLSP receptor, IL-33 receptor, and IL-25, it was found

that ILC2 can produce IL-5 in the skin, indicating that skin microenvironment exists factors to maintain the immune function of ILC2 in the skin. According to the transcriptomic signatures

imprinted by each tissue, the expression of _Il18α__r_ in skin ILC2 is significantly higher than ILC2s in other tissues. And it has been proved that the presence of IL-18 can enhance the

production of IL-13 in skin ILC2s and maintain the steady-state activation of skin ILC2s. The article points out that factors derived from different tissues contribute to the activation of

the ILC2 subgroup in the steady state. Later, this study also conducted transcriptional profiling analysis on various tissues, such as the lung, fat, and gut, and found that ILC2 from

different tissues was tissue-specific and independent of epithelial cytokines [70]. The phenotype of tissue ILC2 can change with changes in the culture environment. Qiu et al. has found the

phenotypes of ILC2 from gut, pancreas and lung changed while respectively cultured with tissue cells that were different from the source of tissue ILC2. Then they indicated that the tissue

microenvironment actively shaped ILC2 characters [12]. In addition, studies have shown that Nrp1 is a specific marker of lung ILC2, playing an important role in ILC2 function, and the

expression of Nrp1 is induced and maintained by the lung microenvironment. This experiment co-culture ILC2 isolated from the lungs and intestines with monocytes from lung and intestinal

tissues to explore the adaptation of tissue ILC2 to environmental cues. The Nrp1 expression of intestinal ILC2 co-cultured with lung cells was upregulated, while the Nrp1 expression of lung

ILC2 co-cultured with intestinal cells was inhibited. These findings demonstrated that the expression of Nrp1 required lung environment signals to induce and maintain. Compared with other

tissues, lung has the highest expression level of TGF-b1, which is the ligand of TGFβ1. And TGFβ1 has been confirmed to have a direct relationship with the maintenance of Nrp1 expression

[55]. ILC2 FUNCTIONS BE REGULATED BY DISTAL OR PROXIMAL TISSUE MICROENVIRONMENT Interestingly, in addition to being influenced by tissue microenvironments, ILC2 also can interact with distal

or proximal organs. This tissue crosstalk not only can be caused by ILC2 migration but also induces the transformation, activation, and inhibition of tissue-resident ILC2. ALTERATIONS IN

THE TISSUE MICROENVIRONMENT INDUCE ILC2S TO ACQUIRE MIGRATORY CAPACITY Initially, ILCs were identified in both lymphoid and non-lymphoid organs as tissue-resident cells, and the tissue

residency of ILCs, including ILC2s, was even maintained under systemic inflammation created by the deficiency of FOXP3 in mice [71]. However, recent studies have shown that the resident-ILC2

in lung and gut can migrate between lung and gut, which is accompanied by the subset transformation of ILC2. Huang et al. identified another cell subtype of ILC2 distinct from nILC2: iILC2,

which is thought to be a transient progenitor of inflammatory and infective ILCs that replenish nILC2 and contribute to immunity against worms and fungi [53]. And a subsequent study by

Huang et al. found that nILC2 in the gut can proliferate and transform to migratory iILC2 after being activated by IL-25. The iILC2s migrated similarly to T lymphocytes. They depended on S1P

entering lymphatic vessels and then entering the circulatory system, which mostly raised in the lung to exert effects of tissue repair and anti-helminth infection [13]. (Fig. 4) In addition

to the migration of ILC2 from gut to lung, a paper in 2022 indicated that ILC2 can migrate and develop from lung to gut. Zhao et al. found that the ILC2 in the lung and gut respectively

express CCR2 or CCR4, and took the expression level of _GATA3_ and _Klrg1_ as maturity index to detect the maturity degree of ILC2 from the gut to the lung. Then, they found that ILC2,

migrating from the lungs to the intestine, matures gradually from lung to intestine. Notably, further research on ILC2 development revealed that lung CCR2+ ILC2 produced gut CCR4+ ILC2. And

it was discovered that the CCR2+CCR4+ ILC2 existed in the gut, suggesting that these ILC2s may have undergone a transition from CCR2+ ILC2s to CCR4+ ILC2s. (Fig. 4) The above findings

indicated that lung ILC2 gradually migrates and develops into the intestine, and subtypes change during migration to adapt to the intestinal environment [54]. The microenvironment change can

not only induce migration of ILC2 to other tissues but also promote migration of ILC2 from the adventitial niches to tissue parenchymal sites. Cautivo et al. found activation of type 2

immunity induced by IL-33 or infection with _Nippostrongylus brasiliensis_ helminths could induce lung IL-5+ ILC2, distributing in adventitial niches around larger vessels and airways,

migrate to de novo parenchymal sites. This phenomenon is also observed in the liver and perigonadal adipose tissue, innate and adaptive type 2 responses leading to the expansion and

appearance of IL-5+ ILC2 within parenchymal areas in proximity to hepatocytes. And the restriction of ILC2 migration to tissue parenchyma can be induced by the type I immune factor IFN- γ,

which causes a reduction in type 2 inflammation and worsening of worm infection. The authors stated that the regulation of ILC2 migration within organizations was a critical determinant of

beneficial and pathologic organ inflammation and repair [72]. Moreover, the migration of ILC2 also contributes to systemic inflammation. It has been found that cutaneous local innate

responses can be amplified to systemic type 2 responses by activated ILC2s migrating from the skin into the draining lymph node [73]. THE FUNCTIONS OF ILC2 ARE INFLUENCED BY MUCOSAL

NEURO-LUNG CROSSTALK Neuronal signals have emerged as pivotal regulators of ILC2s that regulate tissue homeostasis and allergic inflammation. Neuromedin U (NmU) is a group of neuropeptides

secreted by neurons located near immune cells, which has been proven to activate immune cells directly and play a critical role in neurogenic inflammation [74]. Previous studies revealed

that the gene _NMUR1_ was selectively enriched in mouse ILC2s and human ILC2s also express NMUR1, which indicated that ILC2s could accept the stimulation of NMU. And the expression of

pro-inflammation and tissue-protective type 2 cytokines genes, _IL5, IL13_, Areg and colony-stimulating factor 2 (_Csf2_), increased after lung-derived ILC2 was activated with NMU. Notably,

the ILC2-autonomous ablation of _Nmur1_ induced downregulation of type 2 response and reduced the immune resistance to worm infections. In septic mice, NUM was also critical for promoting

IL-17A- producing γδ T cell expansion and expression of IL-17A by activating lung ILC2. These researches indicated that the NMU-NMUR1 axis plays an important role in the production of

ILC2-derived cytokines, and paracrine neurons can direct the sense of exogenous antigen and alarmins and produce NMU to enhance innate type 2 immunity for providing immediate mucosal

protection [47, 75]. What’s more, NMU can amplify the stimulation of alarmin (IL-25) to ILC2s. According to previous research, lung ILC2s can be activated to proliferate and highly express

IL-13, the effect factor of ILC2, after being treated with IL-25 and NMU [76]. Interestingly, the nerve signals not only enhance ILC2 function but also suppress ILC2 activation. Dopamine, an

essential neurotransmitter that relates to immune cell activity and alleviates inflammation [3], can inhibit lung ILC2 responses in allergic airway inflammation by impairing the function of

the mitochondrion in ILC2 via the oxidative phosphorylation pathway [77]. Neuropeptide CGRP suppresses IL-33-induced pulmonary inflammation and worm expulsion of _N. brasiliensis_ by

inhibiting the immune response of ILC2s. Interestingly, CGRP plays a role in slamming on the brake of activation of ILC2s by NMU. CGRP receptor expression increased at a later time point

following infection, whereas Nmur1 expression in ILC2s was downregulated. The results show that the nervous system can participate in the regulation of lung immunity by stimulating or

suppressing the activation of lung ILC2 through secreted nerve signals [78]. TISSUE MICROENVIRONMENT INDUCES THE TRANSDIFFERENTIATION OF ILC2S Recent studies have shown that under the

influence of diseases, the composition of tissue ILCs changes due to the transdifferentiation of one ILC into another, including the transformation of ILC2 into ILC1 and ILC3, which can

further disrupt tissue function. The transdifferentiation of ILC2 is similar to the transformation between ILC2 subgroups, which were accompanied by the change of transcriptional profile,

phenotype, and function. Research has shown that lung ILC2s isolated from chronic obstructive pulmonary disease (COPD) could transdifferentiate into ILC1s when stimulated by IL-β and IL-12,

with the reduction of GATA3 transcripts and GATA3 protein expression and upregulation of T-bet expression, while IL-4 can restore the functional characteristics of ILC2. These demonstrated

that lung ILC2s had the potential to transdifferentiate into ILC1s when exposed to a type 1 inflammatory environment, such as COPD. Meanwhile, this study also observed that CRTH2- ILC2 from

peripheral blood and nasal polyps of patients with chronic sinusitis has low expression of _GATA3_ mRNA and high expression of _TBX21_ mRNA and _RORC_ mRNA, and can secrete IFN-γ in response

to type 1 stimulation, which indicated that the occurrence of chronic sinusitis promoted ILC2s to acquire the character of producing IFN-γ ILC1. Therefore, imbalance of IL-4, IL-12 and

IL-1β may cause disorder in the transdifferentiation of ILC2 and ILC1, resulting in the perpetuation of type 1 or type 2 inflammation [79, 80]. In 2019, Bernink et al. revealed that ILC2s

had the potential to transform into ILC3-like cell population capable of producing IL-17 and referred that the downregulation of GATA-3 expression is an essential factor for ILC2s to

transdifferentiate into ILC3 like cells, which can be caused by IL-23 and TGF- β in skin microenvironment. Further, this research compared normal skin specimens with biopsies of patients

with psoriasis and found a significant increase in the frequency of NKp44- ILC3s, which was associated with a decrease in CRTH2+ ILC2s derived from the dermis of psoriatic lesions, and above

results demonstrate that the ILC3 increase within skin lesions of patients might result from an increased shift of ILC2 toward ILC2-derived ILC3s [15]. And this conclusion was proved in

2020 by Bielecki et al. by structuring the topic model of ILC scRNA-seq time in psoriasis induced by IL-23 and using their directed-diffusion method to calculate the time trajectory of ILC3

differentiation. Research data suggest that the resting ILC2 population in the skin can specifically transdifferentiate into an ILC3-like subgroup in psoriasis induced by IL-23 or imiquimod

and participate in the immune response of psoriasis to promote skin inflammation [64]. CONCLUSION In contrast to previous views, ILC2s are heterogeneous cells that undergo changes in gene

profile, transcriptional profile, and phenotype based on changes in the tissue microenvironment. Tissue microenvironments induce ILC2s tissue-specificity to adapt to the tissue environment

and involve tissue immune responses by influencing the differentiation of congenital lymphoid progenitor cells and secreting cytokines. At present, ILC2 subgroups with tissue specificity

have been found in several organizations, indicating that the tissue specificity of ILC2 is universal. However, there are still insufficient studies to demonstrate whether tissue

heterogeneity of ILC2 has an impact on ILC2 function. In addition, crosstalk of tissues can cause transdifferentiation from intrinsic ILC2 to migratory ILC2, as well as activation and

inhibition of ILC2 function, indicating that the regulation of ILC2 in an organization is not only related to the microenvironment of the organization but also to signaling molecules in

other tissues. ILC2s are highly dynamic cells that respond, migrate, and transdifferent depending on the microenvironment. Thus, ILC2s are easily dysregulated and caused by abnormal

microenvironment, resulting in diseases such as inflammation, allergic disease, and disordered tissue repair. Hence, maintaining the stability and balance of ILC2 should be considered one of

the critical factors in maintaining tissue homeostasis. REFERENCES * Maggi L, Mazzoni A, Capone M, Liotta F, Annunziato F, Cosmi L. The dual function of ILC2: From host protection to

pathogenic players in type 2 asthma. Mol Asp Med. 2021;80:100981 https://doi.org/10.1016/j.mam.2021.100981. Article  CAS  Google Scholar  * Jarick KJ, Topczewska PM, Jakob MO, Yano H,

Arifuzzaman M, Gao X, et al. Non-redundant functions of group 2 innate lymphoid cells. Nature. 2022;611:794–800. https://doi.org/10.1038/s41586-022-05395-5. Article  CAS  PubMed  PubMed

Central  Google Scholar  * Klose CS, Artis D. Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat Immunol. 2016;17:765–74.

https://doi.org/10.1038/ni.3489. Article  CAS  PubMed  Google Scholar  * Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517:293–301.

https://doi.org/10.1038/nature14189. Article  CAS  PubMed  Google Scholar  * Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of

interleukin-4 (IL-4) and IL-13 production. Cytokine. 2015;75:14–24. https://doi.org/10.1016/j.cyto.2015.05.010. Article  CAS  PubMed  PubMed Central  Google Scholar  * Vivier E, Artis D,

Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate Lymphoid Cells: 10 Years On. Cell. 2018;174:1054–66. https://doi.org/10.1016/j.cell.2018.07.017. Article  CAS  PubMed  Google

Scholar  * Schuijs MJ, Halim TYF. Group 2 innate lymphocytes at the interface between innate and adaptive immunity. Ann N Y Acad Sci. 2018;1417:87–103. https://doi.org/10.1111/nyas.13604.

Article  CAS  PubMed  Google Scholar  * Wong SH, Walker JA, Jolin HE, Drynan LF, Hams E, Camelo A, et al. Transcription factor RORα is critical for nuocyte development. Nat Immunol.

2012;13:229–36. https://doi.org/10.1038/ni.2208. Article  CAS  PubMed  PubMed Central  Google Scholar  * Simoni Y, Fehlings M, Kløverpris HN, McGovern N, Koo SL, Loh CY, et al. Human Innate

Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency. Immunity. 2017;46:148–61. https://doi.org/10.1016/j.immuni.2016.11.005. Article  CAS  PubMed  Google

Scholar  * Olguín-Martínez E, Ruiz-Medina BE, Licona-Limón P. Tissue-Specific Molecular Markers and Heterogeneity in Type 2 Innate Lymphoid Cells. Front Immunol. 2021;12:757967

https://doi.org/10.3389/fimmu.2021.757967. Article  CAS  PubMed  PubMed Central  Google Scholar  * Mazzurana L, Czarnewski P, Jonsson V, Wigge L, Ringnér M, Williams TC, et al.

Tissue-specific transcriptional imprinting and heterogeneity in human innate lymphoid cells revealed by full-length single-cell RNA-sequencing. Cell Res. 2021;31:554–68.

https://doi.org/10.1038/s41422-020-00445-x. Article  CAS  PubMed  PubMed Central  Google Scholar  * Qiu J, Zhang J, Ji Y, Sun H, Gu Z, Sun Q, et al. Tissue signals imprint Aiolos expression

in ILC2s to modulate type 2 immunity. Mucosal Immunol. 2021;14:1306–22. https://doi.org/10.1038/s41385-021-00431-5. Article  CAS  PubMed  PubMed Central  Google Scholar  * Huang Y, Mao K,

Chen X, Sun MA, Kawabe T, Li W, et al. S1P-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense. Science. 2018;359:114–9.

https://doi.org/10.1126/science.aam5809. Article  CAS  PubMed  PubMed Central  Google Scholar  * Moriyama S, Artis D. Neuronal regulation of group 2 innate lymphoid cells and type 2

inflammation. Adv Immunol. 2019;143:1–9. https://doi.org/10.1016/bs.ai.2019.08.001. Article  CAS  PubMed  Google Scholar  * Bernink JH, Ohne Y, Teunissen MBM, Wang J, Wu J, Krabbendam L, et

al. c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies. Nat Immunol. 2019;20:992–1003. https://doi.org/10.1038/s41590-019-0423-0. Article 

CAS  PubMed  Google Scholar  * Thio CL, Chang YJ. The modulation of pulmonary group 2 innate lymphoid cell function in asthma: from inflammatory mediators to environmental and metabolic

factors. Exp Mol Med. 2023;55:1872–84. https://doi.org/10.1038/s12276-023-01021-0. Article  CAS  PubMed  PubMed Central  Google Scholar  * Colonna M. Innate Lymphoid Cells: Diversity,

Plasticity, and Unique Functions in Immunity. Immunity. 2018;48:1104–17. https://doi.org/10.1016/j.immuni.2018.05.013. Article  CAS  PubMed  PubMed Central  Google Scholar  * Walker JA,

Oliphant CJ, Englezakis A, Yu Y, Clare S, Rodewald H-R, et al. Bcl11b is essential for group 2 innate lymphoid cell development. J Exp Med. 2015;212:875–82. * Serafini N, Vosshenrich CA, Di

Santo JP. Transcriptional regulation of innate lymphoid cell fate. Nat Rev Immunol. 2015;15:415–28. https://doi.org/10.1038/nri3855. Article  CAS  PubMed  Google Scholar  * Yao HC, Zhu Y, Lu

HY, Ju HM, Xu SQ, Qiao Y, et al. Type 2 innate lymphoid cell-derived amphiregulin regulates type II alveolar epithelial cell transdifferentiation in a mouse model of bronchopulmonary

dysplasia. Int Immunopharmacol. 2023;122:110672 https://doi.org/10.1016/j.intimp.2023.110672. Article  CAS  PubMed  Google Scholar  * van Rijt L, von Richthofen H, van Ree R. Type 2 innate

lymphoid cells: at the cross-roads in allergic asthma. Semin Immunopathol. 2016;38:483–96. https://doi.org/10.1007/s00281-016-0556-2. Article  CAS  PubMed  PubMed Central  Google Scholar  *

Xiao Q, Han X, Liu G, Zhou D, Zhang L, He J, et al. Adenosine restrains ILC2-driven allergic airway inflammation via A2A receptor. Mucosal Immunol. 2022;15:338–50.

https://doi.org/10.1038/s41385-021-00475-7. Article  CAS  PubMed  Google Scholar  * Fu L, Zhao J, Huang J, Li N, Dong X, He Y, et al. A mitochondrial STAT3-methionine metabolism axis

promotes ILC2-driven allergic lung inflammation. J allergy Clin Immunol. 2022;149:2091–104. https://doi.org/10.1016/j.jaci.2021.12.783. Article  CAS  PubMed  Google Scholar  * Helou DG,

Shafiei-Jahani P, Lo R, Howard E, Hurrell BP, Galle-Treger L, et al. PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity. Nat Commun.

2020;11:3998 https://doi.org/10.1038/s41467-020-17813-1. Article  CAS  PubMed  PubMed Central  Google Scholar  * Huang Y, Paul WE. Inflammatory group 2 innate lymphoid cells. Int Immunol.

2016;28:23–8. https://doi.org/10.1093/intimm/dxv044. Article  CAS  PubMed  Google Scholar  * Cai T, Qiu J, Ji Y, Li W, Ding Z, Suo C, et al. IL-17-producing ST2(+) group 2 innate lymphoid

cells play a pathogenic role in lung inflammation. J allergy Clin Immunol. 2019;143:229–.e229. https://doi.org/10.1016/j.jaci.2018.03.007. Article  CAS  PubMed  Google Scholar  * Hartung F,

Esser-von Bieren J. Trained immunity in type 2 immune responses. Mucosal Immunol. 2022;15:1158–69. https://doi.org/10.1038/s41385-022-00557-0. Article  CAS  PubMed  PubMed Central  Google

Scholar  * McKenzie GJ, Bancroft A, Grencis RK, McKenzie AN. A distinct role for interleukin-13 in Th2-cell-mediated immune responses. Curr Biol. 1998;8:339–42.

https://doi.org/10.1016/s0960-9822(98)70134-4. Article  CAS  PubMed  Google Scholar  * Nussbaum JC, Van Dyken SJ, von Moltke J, Cheng LE, Mohapatra A, Molofsky AB, et al. Type 2 innate

lymphoid cells control eosinophil homeostasis. Nature. 2013;502:245–8. https://doi.org/10.1038/nature12526. Article  CAS  PubMed  PubMed Central  Google Scholar  * Akdis CA, Arkwright PD,

Brüggen MC, Busse W, Gadina M, Guttman-Yassky E, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75:1582–605. https://doi.org/10.1111/all.14318. Article  CAS  PubMed  Google

Scholar  * Takatsu K, Nakajima H. IL-5 and eosinophilia. Curr Opin Immunol. 2008;20:288–94. https://doi.org/10.1016/j.coi.2008.04.001. Article  CAS  PubMed  Google Scholar  * Wilhelm C,

Hirota K, Stieglitz B, Van Snick J, Tolaini M, Lahl K, et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol. 2011;12:1071–7.

https://doi.org/10.1038/ni.2133. Article  CAS  PubMed  PubMed Central  Google Scholar  * Rauber S, Luber M, Weber S, Maul L, Soare A, Wohlfahrt T, et al. Resolution of inflammation by

interleukin-9-producing type 2 innate lymphoid cells. Nat Med. 2017;23:938–44. https://doi.org/10.1038/nm.4373. Article  CAS  PubMed  PubMed Central  Google Scholar  * Monticelli LA, Osborne

LC, Noti M, Tran SV, Zaiss DM, Artis D. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci USA.

2015;112:10762–7. https://doi.org/10.1073/pnas.1509070112. Article  CAS  PubMed  PubMed Central  Google Scholar  * Zaiss DMW, Gause WC, Osborne LC, Artis D. Emerging functions of

amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity. 2015;42:216–26. https://doi.org/10.1016/j.immuni.2015.01.020. Article  CAS  PubMed  PubMed Central  Google

Scholar  * Drake LY, Iijima K, Kita H. Group 2 innate lymphoid cells and CD4+ T cells cooperate to mediate type 2 immune response in mice. Allergy. 2014;69:1300–7.

https://doi.org/10.1111/all.12446. Article  CAS  PubMed  Google Scholar  * Oliphant CJ, Hwang YY, Walker JA, Salimi M, Wong SH, Brewer JM, et al. MHCII-mediated dialog between group 2 innate

lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity. 2014;41:283–95. https://doi.org/10.1016/j.immuni.2014.06.016. Article  CAS

  PubMed  PubMed Central  Google Scholar  * Zaiss DMW, Pearce EJ, Artis D, McKenzie ANJ, Klose CSN. Cooperation of ILC2s and T(H)2 cells in the expulsion of intestinal helminth parasites.

Nat Rev Immunol. 2023. https://doi.org/10.1038/s41577-023-00942-1. Article  PubMed  Google Scholar  * Janeway CA Jr. The priming of helper T cells. Semin Immunol. 1989;1:13–20. CAS  PubMed 

Google Scholar  * Gurram RK, Wei D, Yu Q, Butcher MJ, Chen X, Cui K, et al. Crosstalk between ILC2s and Th2 cells varies among mouse models. Cell Rep. 2023;42:112073

https://doi.org/10.1016/j.celrep.2023.112073. Article  CAS  PubMed  PubMed Central  Google Scholar  * Pelly VS, Kannan Y, Coomes SM, Entwistle LJ, Rückerl D, Seddon B, et al. IL-4-producing

ILC2s are required for the differentiation of T(H)2 cells following Heligmosomoides polygyrus infection. Mucosal Immunol. 2016;9:1407–17. https://doi.org/10.1038/mi.2016.4. Article  CAS 

PubMed  PubMed Central  Google Scholar  * Halim TY, Hwang YY, Scanlon ST, Zaghouani H, Garbi N, Fallon PG, et al. Group 2 innate lymphoid cells license dendritic cells to potentiate memory

TH2 cell responses. Nat Immunol. 2016;17:57–64. https://doi.org/10.1038/ni.3294. Article  CAS  PubMed  Google Scholar  * Moretti S, Renga G, Oikonomou V, Galosi C, Pariano M, Iannitti RG, et

al. A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis. Nat Commun. 2017;8:14017 https://doi.org/10.1038/ncomms14017. Article  CAS  PubMed  PubMed Central  Google

Scholar  * Domvri K, Petanidis S, Zarogoulidis P, Anestakis D, Tsavlis D, Bai C, et al. Treg-dependent immunosuppression triggers effector T cell dysfunction via the STING/ILC2 axis. Clin

Immunol. 2021;222:108620 https://doi.org/10.1016/j.clim.2020.108620. Article  CAS  PubMed  Google Scholar  * Noval Rivas M, Burton OT, Oettgen HC, Chatila T. IL-4 production by group 2

innate lymphoid cells promotes food allergy by blocking regulatory T-cell function. J Allergy Clin Immunol. 2016;138:801–11.e809. https://doi.org/10.1016/j.jaci.2016.02.030. Article  CAS 

PubMed  Google Scholar  * Halim TYF, Rana BMJ, Walker JA, Kerscher B, Knolle MD, Jolin HE, et al. Tissue-Restricted Adaptive Type 2 Immunity Is Orchestrated by Expression of the

Costimulatory Molecule OX40L on Group 2 Innate Lymphoid Cells. Immunity. 2018;48:1195–1207.e1196. https://doi.org/10.1016/j.immuni.2018.05.003. Article  CAS  PubMed  PubMed Central  Google

Scholar  * Chen W, Lai D, Li Y, Wang X, Pan Y, Fang X, et al. Neuronal-Activated ILC2s Promote IL-17A Production in Lung γδ T Cells During Sepsis. Front Immunol. 2021;12:670676

https://doi.org/10.3389/fimmu.2021.670676. Article  CAS  PubMed  PubMed Central  Google Scholar  * Spits H, Mjösberg J. Heterogeneity of type 2 innate lymphoid cells. Nat Rev Immunol.

2022;22:701–12. https://doi.org/10.1038/s41577-022-00704-5. Article  CAS  PubMed  PubMed Central  Google Scholar  * Seehus CR, Kadavallore A, Torre B, Yeckes AR, Wang Y, Tang J, et al.

Alternative activation generates IL-10 producing type 2 innate lymphoid cells. Nat Commun. 2017;8:1900 https://doi.org/10.1038/s41467-017-02023-z. Article  CAS  PubMed  PubMed Central 

Google Scholar  * Golebski K, Layhadi JA, Sahiner U, Steveling-Klein EH, Lenormand MM, Li RCY, et al. Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is

associated with clinical response. Immunity. 2021;54:291–307.e297. https://doi.org/10.1016/j.immuni.2020.12.013. Article  CAS  PubMed  Google Scholar  * Bando, JK, Gilfillan, S, Di Luccia,

B, Fachi, JL, Sécca, C, Cella, M et al. ILC2s are the predominant source of intestinal ILC-derived IL-10. J Exp Med. 2020;217. https://doi.org/10.1084/jem.20191520. * Hochdörfer T, Winkler

C, Pardali K, Mjösberg J. Expression of c-Kit discriminates between two functionally distinct subsets of human type 2 innate lymphoid cells. Eur J Immunol. 2019;49:884–93.

https://doi.org/10.1002/eji.201848006. Article  CAS  PubMed  Google Scholar  * Huang Y, Guo L, Qiu J, Chen X, Hu-Li J, Siebenlist U, et al. IL-25-responsive, lineage-negative KLRG1(hi) cells

are multipotential ‘inflammatory’ type 2 innate lymphoid cells. Nat Immunol. 2015;16:161–9. https://doi.org/10.1038/ni.3078. Article  CAS  PubMed  Google Scholar  * Zhao M, Shao F, Yu D,

Zhang J, Liu Z, Ma J, et al. Maturation and specialization of group 2 innate lymphoid cells through the lung-gut axis. Nat Commun. 2022;13:7600 https://doi.org/10.1038/s41467-022-35347-6.

Article  CAS  PubMed  PubMed Central  Google Scholar  * Zhang J, Qiu J, Zhou W, Cao J, Hu X, Mi W, et al. Neuropilin-1 mediates lung tissue-specific control of ILC2 function in type 2

immunity. Nat Immunol. 2022;23:237–50. https://doi.org/10.1038/s41590-021-01097-8. Article  CAS  PubMed  Google Scholar  * Abidi A, Laurent T, Bériou G, Bouchet-Delbos L, Fourgeux C, Louvet

C, et al. Tissue signals imprint ILC2 identity with anticipatory function. Front Immunol. 2020;11:255 https://doi.org/10.3389/fimmu.2020.00255. Article  CAS  PubMed  PubMed Central  Google

Scholar  * Orimo K, Tamari M, Saito H, Matsumoto K, Nakae S, Morita H. Characteristics of tissue-resident ILCs and their potential as therapeutic targets in mucosal and skin inflammatory

diseases. Allergy. 2021;76:3332–48. https://doi.org/10.1111/all.14863. Article  CAS  PubMed  Google Scholar  * Ualiyeva S, Lemire E, Aviles EC, Wong C, Boyd AA, Lai J, et al. Tuft

cell-produced cysteinyl leukotrienes and IL-25 synergistically initiate lung type 2 inflammation. Sci Immunol. 2021;6:eabj0474 https://doi.org/10.1126/sciimmunol.abj0474. Article  CAS 

PubMed  PubMed Central  Google Scholar  * Nii T, Fukushima K, Kida H. Specific targeting of lung ILC2s via NRP1 in pulmonary fibrosis. Cell Mol Immunol. 2022;19:869–71.

https://doi.org/10.1038/s41423-022-00867-0. Article  CAS  PubMed  PubMed Central  Google Scholar  * Wang Z, Yan C, Du Q, Huang Y, Li X, Zeng D, et al. HTR2A agonists play a therapeutic role

by restricting ILC2 activation in papain-induced lung inflammation. Cell Mol Immunol. 2023;20:404–18. https://doi.org/10.1038/s41423-023-00982-6. Article  CAS  PubMed  PubMed Central  Google

Scholar  * Ghaedi, M, Shen, ZY, Orangi, M, Martinez-Gonzalez, I, Wei, L, Lu, X et al. Single-cell analysis of RORα tracer mouse lung reveals ILC progenitors and effector ILC2 subsets. J Exp

Med. 2020;217. https://doi.org/10.1084/jem.20182293. * Li S, Bostick JW, Ye J, Qiu J, Zhang B, Urban JF Jr, et al. Aryl Hydrocarbon Receptor Signaling Cell Intrinsically Inhibits Intestinal

Group 2 Innate Lymphoid Cell Function. Immunity. 2018;49:915–28.e915. https://doi.org/10.1016/j.immuni.2018.09.015. Article  CAS  PubMed  PubMed Central  Google Scholar  * Roediger B, Kyle

R, Yip KH, Sumaria N, Guy TV, Kim BS, et al. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat Immunol. 2013;14:564–73.

https://doi.org/10.1038/ni.2584. Article  CAS  PubMed  PubMed Central  Google Scholar  * Bielecki P, Riesenfeld SJ, Hütter JC, Torlai Triglia E, Kowalczyk MS, Ricardo-Gonzalez RR, et al.

Skin-resident innate lymphoid cells converge on a pathogenic effector state. Nature. 2021;592:128–32. https://doi.org/10.1038/s41586-021-03188-w. Article  CAS  PubMed  PubMed Central  Google

Scholar  * Bando JK, Liang HE, Locksley RM. Identification and distribution of developing innate lymphoid cells in the fetal mouse intestine. Nat Immunol. 2015;16:153–60.

https://doi.org/10.1038/ni.3057. Article  CAS  PubMed  Google Scholar  * Schneider C, Lee J, Koga S, Ricardo-Gonzalez RR, Nussbaum JC, Smith LK, et al. Tissue-Resident Group 2 Innate

Lymphoid Cells Differentiate by Layered Ontogeny and In Situ Perinatal Priming. Immunity. 2019;50:1425–38.e1425. https://doi.org/10.1016/j.immuni.2019.04.019. Article  CAS  PubMed  PubMed

Central  Google Scholar  * Zeis P, Lian M, Fan X, Herman JS, Hernandez DC, Gentek R, et al. In Situ Maturation and Tissue Adaptation of Type 2 Innate Lymphoid Cell Progenitors. Immunity.

2020;53:775–92.e779. https://doi.org/10.1016/j.immuni.2020.09.002. Article  CAS  PubMed  PubMed Central  Google Scholar  * Campana S, De Pasquale C, Barberi C, Oliveri D, Sidoti Migliore G,

Galletti B, et al. Circulating ILC precursors expressing CD62L exhibit a type 2 signature distinctly decreased in psoriatic patients. Eur J Immunol. 2021;51:1792–8.

https://doi.org/10.1002/eji.202048893. Article  CAS  PubMed  PubMed Central  Google Scholar  * Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, et al. A role for IL-25 and

IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013;210:2939–50. https://doi.org/10.1084/jem.20130351. Article  CAS  PubMed  PubMed Central  Google Scholar  *

Ricardo-Gonzalez RR, Van Dyken SJ, Schneider C, Lee J, Nussbaum JC, Liang HE, et al. Tissue signals imprint ILC2 identity with anticipatory function. Nat Immunol. 2018;19:1093–9.

https://doi.org/10.1038/s41590-018-0201-4. Article  CAS  PubMed  PubMed Central  Google Scholar  * Gasteiger G, Fan X, Dikiy S, Lee SY, Rudensky AY. Tissue residency of innate lymphoid cells

in lymphoid and nonlymphoid organs. Science. 2015;350:981–5. https://doi.org/10.1126/science.aac9593. Article  CAS  PubMed  PubMed Central  Google Scholar  * Cautivo KM, Matatia PR, Lizama

CO, Mroz NM, Dahlgren MW, Yu X, et al. Interferon gamma constrains type 2 lymphocyte niche boundaries during mixed inflammation. Immunity. 2022;55:254–71.e257.

https://doi.org/10.1016/j.immuni.2021.12.014. Article  CAS  PubMed  PubMed Central  Google Scholar  * Nakatani-Kusakabe M, Yasuda K, Tomura M, Nagai M, Yamanishi K, Kuroda E, et al.

Monitoring Cellular Movement with Photoconvertible Fluorescent Protein and Single-Cell RNA Sequencing Reveals Cutaneous Group 2 Innate Lymphoid Cell Subtypes, Circulating ILC2 and

Skin-Resident ILC2. JID Innov. 2021;1:100035 https://doi.org/10.1016/j.xjidi.2021.100035. Article  PubMed  PubMed Central  Google Scholar  * Ye Y, Liang Z, Xue L. Neuromedin U: potential

roles in immunity and inflammation. Immunology. 2021;162:17–29. https://doi.org/10.1111/imm.13257. Article  CAS  PubMed  Google Scholar  * Cardoso V, Chesné J, Ribeiro H, García-Cassani B,

Carvalho T, Bouchery T, et al. Neuronal regulation of type 2 innate lymphoid cells via neuromedin U. Nature. 2017;549:277–81. https://doi.org/10.1038/nature23469. Article  CAS  PubMed 

PubMed Central  Google Scholar  * Wallrapp A, Riesenfeld SJ, Burkett PR, Abdulnour RE, Nyman J, Dionne D, et al. The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation.

Nature. 2017;549:351–6. https://doi.org/10.1038/nature24029. Article  CAS  PubMed  PubMed Central  Google Scholar  * Cao Y, Li Y, Wang X, Liu S, Zhang Y, Liu G, et al. Dopamine inhibits

group 2 innate lymphoid cell-driven allergic lung inflammation by dampening mitochondrial activity. Immunity. 2023;56:320–35.e329. https://doi.org/10.1016/j.immuni.2022.12.017. Article  CAS

  PubMed  Google Scholar  * Nagashima H, Mahlakõiv T, Shih HY, Davis FP, Meylan F, Huang Y, et al. Neuropeptide CGRP Limits Group 2 Innate Lymphoid Cell Responses and Constrains Type 2

Inflammation. Immunity. 2019;51:682–95.e686. https://doi.org/10.1016/j.immuni.2019.06.009. Article  CAS  PubMed  PubMed Central  Google Scholar  * Bal SM, Bernink JH, Nagasawa M, Groot J,

Shikhagaie MM, Golebski K, et al. IL-1β, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat Immunol. 2016;17:636–45.

https://doi.org/10.1038/ni.3444. Article  CAS  PubMed  Google Scholar  * Wang ZM, Zhang J, Wang F, Zhou G. The Tipped Balance of ILC1/ILC2 in Peripheral Blood of Oral Lichen Planus Is

Related to Inflammatory Cytokines. Front Cell Dev Biol. 2021;9:725169 https://doi.org/10.3389/fcell.2021.725169. Article  PubMed  Google Scholar  Download references ACKNOWLEDGEMENTS The

figures created with BioRender.com. FUNDING This work of appreciation was due to the National Natural Science Foundation of China (82374123, 82274101, and 81903803); The Natural Science

Foundation of Zhejiang Province (LY24H280002). AUTHOR INFORMATION Author notes * These authors contributed equally: Minjing Qin, Yuanyuan Fang. AUTHORS AND AFFILIATIONS * School of Pharmacy,

Zhejiang Chinese Medical University, Hangzhou, China Minjing Qin, Yuanyuan Fang, Qitong Zheng, Mengyun Peng, Lu Wang, Xia’nan Sang & Gang Cao Authors * Minjing Qin View author

publications You can also search for this author inPubMed Google Scholar * Yuanyuan Fang View author publications You can also search for this author inPubMed Google Scholar * Qitong Zheng

View author publications You can also search for this author inPubMed Google Scholar * Mengyun Peng View author publications You can also search for this author inPubMed Google Scholar * Lu

Wang View author publications You can also search for this author inPubMed Google Scholar * Xia’nan Sang View author publications You can also search for this author inPubMed Google Scholar

* Gang Cao View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS Minjin Qin, Yuanyuan Fang are the primary writers in this manuscript. Qitong

Zheng, Mengyun Peng, Lu Wang participated in the writing of this manuscript. Xia’nan Sang and Gang Cao designed and revision the whole manuscript and wrote the manuscript. All authors read

and approved the final manuscript. CORRESPONDING AUTHORS Correspondence to Xia’nan Sang or Gang Cao. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests.

ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND PERMISSIONS OPEN

ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format,

as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third

party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the

article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright

holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Qin, M., Fang, Y., Zheng, Q. _et

al._ Tissue microenvironment induces tissue specificity of ILC2. _Cell Death Discov._ 10, 324 (2024). https://doi.org/10.1038/s41420-024-02096-y Download citation * Received: 24 March 2024 *

Revised: 04 July 2024 * Accepted: 09 July 2024 * Published: 16 July 2024 * DOI: https://doi.org/10.1038/s41420-024-02096-y SHARE THIS ARTICLE Anyone you share the following link with will

be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt

content-sharing initiative